THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THIS WARRANTBrainstorm Cell Therapeutics Inc. • May 13th, 2014 • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on April 13, 2024 (the “Expiration Date”), 33,334 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.00005 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
SECURITIES EXCHANGE AGREEMENTSecurities Exchange Agreement • May 13th, 2014 • Brainstorm Cell Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
This Securities Exchange Agreement (this “Agreement”) is dated as of _______ __, 2014, between Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and the party identified on the signature page hereto (the “Holder”).
March 20, 2014 Prof. Abraham IsraeliBrainstorm Cell Therapeutics Inc. • May 13th, 2014 • Biological products, (no disgnostic substances)
